Category: Orthopedics
Medical device manufacturers making orthopedic products.
Taunton, Mass.-based OMNIlife Science Inc. will be the exclusive distributor of hip articulation technology made by Societe d'Etudes Recherches Fabrication-Dedienne Sante.
OMNIlife Science Inc. will be the exclusive U.S. distributor of articulation technology used in artificial hips made by a French maker of orthopedic and dental implants.
Taunton, Mass.-based OMNIlife said the deal with Societe d'Etudes Recherches Fabrication-Dedienne Sante will begin as soon as the company receives regulatory approval from the Food & Drug Administration. Further terms of the deal were not announced.
Taunton, Mass.-based Orthopaedic Synergy Inc. plans to acquire French robotic and computer-assisted surgery company Praxim SA for an undisclosed amount.
Orthopaedic Synergy Inc. signed a letter of intent to acquire Praxim SA of France, which makes robotic and computer-assisted surgery devices.
The Taunton, Mass.-based firm, which is the holding company for OMNIlife Science Inc. and Enztec Ltd. of New Zealand, said the deal is aimed at generating shorter product development cycles, according to a press release.
Praxim makes automated systems, software and instruments for total joint arthroplasty procedures. Based in Grenoble, France, the comany also has operations in Santa Clara, Calif., Bethlehem, Pa., Solihull, England, and in the Benelux region, according to its website.
The Food & Drug Administration grants 510(k) clearance to ETEX Corp.'s CarriGen bone graft substitute.
ETEX Corp. won 510(k) clearance from the Food & Drug Administration for its CarriGen bone graft substitute and wasted no time getting the product on the market.
The Cambridge, Mass.-based biotech firm said the nanocrystalline calcium phosphate bone void filler is available for immediate sale through its independent sales force, according to a press release.
Cambridge, Mass.-based Biospace Med inks a distribution deal with Oldelft Benelux to sell its sterEOS 2D/3D X-ray workstation in Belgium, the Netherlands and Luxembourg.
Biospace Med followed up on some good news stateside with a European distribution deal that will see its full-body, low-radiation X-ray workstation hit the market in the Benelux nations.
The Paris, France-based company, which houses its U.S. headquarters in Cambridge, Mass., inked a deal with Oldelft Benelux to distribute its sterEOS 2D/3D X-ray workstation in Belgium, the Netherlands and Luxembourg.
X-spine Systems Inc. licenses interbody cage technology from Gamma Spine, hoping to take the minimally invasive spinal implant technology to market.
By Mary Vanac
X-spine Systems Inc., a maker of implants and instruments for spinal surgery, agreed to an exclusive license with Gamma Spine to develop and distribute the minimally invasive spinal fixation technology invented by a professor of orthopedic bioengineering at the University of Toledo.
ProChon Biotech Ltd. says it's halfway home on its clinical trial of the BioCart knee cartilage treatment.
ProChon Biotech Ltd. says it will likely release the results from expanded clinical trials of its BioCart knee cartilage repair treatment by June.
The Woburn, Mass.-based company, which recently raised about $4 million in a convertible bridge loan to finance the trials, said it's about halfway through the patient enrollment process in the Phase II study and expects results to be released in three months.
ProChon is developing a system to repair damaged cartilage called the BioCart system, which uses proprietary fibroblast growth factor technology to help regenerate damaged cartilage in the knee.
The controversial Menaflex implant goes before the Orthopaedic and Rehabilitation Devices Panel once again on March 23, after months of controversy over the clearance process surrounding the ReGen Biologics knee repair device.
A decision by the Food & Drug Administration, which led to a very public mea culpa by the agency and more than a few bloody noses, will get a second look later this month.
The Menaflex knee implant, manufactured by ReGen Biologics Inc., will go back before the Orthopaedic and Rehabilitation Devices Panel on March 23, according to a press release from the Center for Devices and Radiological Health.